{"filing":{"accession_number":"0001493152-26-024547","cik":"0001679628","ticker":"JUNS","company_name":"JUPITER NEUROSCIENCES, INC.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1679628/000149315226024547/form8-k.htm"},"events":[{"id":9882,"run_id":8661,"accession_number":"0001493152-26-024547","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Jupiter Neurosciences entered into a non-binding Term Sheet with PharmAla Biotech on May 19, 2026, regarding a potential licensing transaction to acquire exclusive U.S. rights to ALA-002, a proprietary MDMA formulation, along with related intellectual property and regulatory materials. The transaction contemplates $3.3M upfront consideration plus substantial development and commercialization milestones up to $63.3M, plus perpetual 3% royalties. While the Term Sheet is explicitly non-binding and contingent on definitive agreements within 90 days, the disclosure of a material acquisition of a drug program with defined consideration and milestone structure constitutes a reportable M\u0026A activity under Item 8.01 and Item 7.01.","company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":705,"accession_number":"0001493152-26-024547","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Jupiter Neurosciences entered into a non-binding Term Sheet with PharmAla Biotech on May 19, 2026, regarding a potential licensing transaction to acquire exclusive U.S. rights to ALA-002, a proprietary MDMA formulation, along with related intellectual property and regulatory materials. The transaction contemplates $3.3M upfront consideration plus substantial development and commercialization milestones up to $63.3M, plus perpetual 3% royalties. While the Term Sheet is explicitly non-binding and contingent on definitive agreements within 90 days, the disclosure of a material acquisition of a drug program with defined consideration and milestone structure constitutes a reportable M\u0026A activity under Item 8.01 and Item 7.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:53:08.710350+00:00","company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","filing_date":"2026-05-20"}]}